telmisartan + metoprolol + cilnidipine

TELMOTO-MCL is a fixed-dose combination antihypertensive medication developed by Admire Lifesciences. It combines three distinct classes of blood pressure-lowering agents: telmisartan, an angiotensin II receptor blocker (ARB); metoprolol succinate, a cardioselective beta-1 adrenergic receptor antagonist; and cilnidipine, a dual L-type and N-type calcium channel blocker (CCB). Telmisartan works by blocking the vasoconstrictor effects of angiotensin II at the AT1 receptor, metoprolol reduces cardiac output and heart rate by antagonizing beta-1 receptors, and cilnidipine provides vasodilation while suppressing sympathetic overactivity through its unique inhibition of N-type calcium channels in addition to L-type channels. This triple combination is typically indicated for patients whose hypertension is not adequately controlled by monotherapy or dual therapy, providing a comprehensive approach to cardiovascular risk management.

Brand names

TELMOTO-MCL